{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:08:51Z","timestamp":1761894531263},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2003,11,1]],"date-time":"2003-11-01T00:00:00Z","timestamp":1067644800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2003,11,1]],"date-time":"2003-11-01T00:00:00Z","timestamp":1067644800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Urol Rep"],"published-print":{"date-parts":[[2003,11]]},"DOI":"10.1007\/s11934-003-0025-z","type":"journal-article","created":{"date-parts":[[2007,6,5]],"date-time":"2007-06-05T20:50:31Z","timestamp":1181076631000},"page":"446-451","source":"Crossref","is-referenced-by-count":31,"title":["Overactive bladder: Improving the efficacy of anticholinergics by dose escalation"],"prefix":"10.1007","volume":"4","author":[{"given":"Scott A.","family":"MacDiarmid","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"25_CR1","unstructured":"Thom DH: Overactive bladder: epidemiology and impact on quality of life. Patient Care 2000:6\u201314."},{"key":"25_CR2","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/S0090-4295(97)00623-7","volume":"51","author":"TH Wagner","year":"1998","unstructured":"Wagner TH, Hu TW: Economic costs of urinary incontinence in 1995. Urology 1998, 51:355\u2013361.","journal-title":"Urology"},{"key":"25_CR3","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/S0090-4295(97)00599-2","volume":"50","author":"RA Appell","year":"1997","unstructured":"Appell RA: Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis. Urology 1997, 50:90\u201396.","journal-title":"Urology"},{"key":"25_CR4","doi-asserted-by":"publisher","first-page":"83","DOI":"10.2165\/00044011-200019020-00001","volume":"19","author":"M Chancellor","year":"2000","unstructured":"Chancellor M, Freedman S, Mitcheson HD, et al.: Tolterodine, an effective and well-tolerated treatment for urge incontinence and other overactive bladder symptoms. Clin Drug Invest 2000, 19:83\u201391.","journal-title":"Clin Drug Invest"},{"key":"25_CR5","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0025-6196(11)62382-3","volume":"76","author":"RA Appell","year":"2001","unstructured":"Appell RA, Sand P, Dmochowski R, et al.: Prospective randomized, controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study. Mayo Clin Proc 2001, 76:358\u2013363.","journal-title":"Mayo Clin Proc"},{"key":"25_CR6","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/S0090-4295(00)01113-4","volume":"57","author":"P Van Kerrebroeck","year":"2001","unstructured":"Van Kerrebroeck P, Kreder K, Jonas U, et al.: Tolterodine oncedaily: superior efficacy and tolerability in the treatment of the overactive bladder. Urology 2001, 57:414\u2013421.","journal-title":"Urology"},{"key":"25_CR7","doi-asserted-by":"publisher","first-page":"687","DOI":"10.4065\/78.6.687","volume":"78","author":"AC Diokno","year":"2003","unstructured":"Diokno AC, Appell RA, Sand PK, et al.: Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA Trial. Mayo Clin Proc 2003, 78:687\u2013695. Well-designed head-to-head study of extended-release oxybutynin versus tolterodine. The efficacy and tolerability of each compound are compared.","journal-title":"Mayo Clin Proc"},{"key":"25_CR8","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/S0022-5347(05)64684-8","volume":"168","author":"RR Dmochowski","year":"2002","unstructured":"Dmochowski RR, Davila GW, Zinner NR, et al.: Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence. J Urol 2002, 168:580\u2013586. The efficacy and tolerability of oxybutynin transdermal delivery system is presented. OXY-TDS has an excellent systemic side-effect profile.","journal-title":"J Urol"},{"key":"25_CR9","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/j.1532-5415.2000.tb04692.x","volume":"48","author":"KL Burgio","year":"2000","unstructured":"Burgio KL, Locher JL, Goode PS: Combined behavioral and drug therapy for urge incontinence in older women. J Am Geriatr Soc 2000, 48:370\u2013374.","journal-title":"J Am Geriatr Soc"},{"key":"25_CR10","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1001\/jama.280.23.1995","volume":"280","author":"KL Burgio","year":"1998","unstructured":"Burgio KL, Locher JL, Goode PS, et al.: Behavioral vs drug treatment for urge urinary incontinence in older women. JAMA 1998, 280:1995\u20132000.","journal-title":"JAMA"},{"key":"25_CR11","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1016\/S0022-5347(05)68810-6","volume":"161","author":"RU Anderson","year":"1999","unstructured":"Anderson RU, Mobley D, Blank B, et al.: Once-daily controlled versus immediate-release oxybutynin chloride for urge urinary incontinence. J Urol 1999, 161:1809\u20131812. This paper illustrates the excellent efficacy that can be achieved with anticholinergics by dose escalation.","journal-title":"J Urol"},{"key":"25_CR12","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/S0029-7844(99)00661-4","volume":"95","author":"E Versi","year":"2000","unstructured":"Versi E, Appell R, Mobley D, et al.: Dry mouth with conventional and controlled-release oxybutynin in urinary incontinence. Obstet Gynecol 2000, 95:718\u2013721.","journal-title":"Obstet Gynecol"},{"key":"25_CR13","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/S0090-4295(99)00259-9","volume":"54","author":"DM Gleason","year":"1999","unstructured":"Gleason DM, Susset J, White C, et al.: Evaluation of a new once-daily formulation of oxybutynin for the treatment of urinary urge incontinence. Urology 1999, 54:420\u2013423.","journal-title":"Urology"},{"key":"25_CR14","doi-asserted-by":"crossref","first-page":"116","DOI":"10.7224\/1537-2073-4.3.116","volume":"4","author":"M O\u2019Leary","year":"2002","unstructured":"O\u2019Leary M, Erickson JR, Smith CP, et al.: Changes in voiding patterns in multiple sclerosis patients with controlled-release oxybutynin. Int J MS Care 2002, 4:116\u2013119.","journal-title":"Int J MS Care"},{"key":"25_CR15","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1080\/10790268.2003.11753678","volume":"26","author":"M O\u2019Leary","year":"2003","unstructured":"O\u2019Leary M, Erickson JR, Smith CP, et al.: The effect of controlled-release oxybutynin on neurogenic bladder function in spinal cord injured patients. J Spinal Cord Med 2003, 26:159\u2013162.","journal-title":"J Spinal Cord Med"},{"key":"25_CR16","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1002\/(SICI)1520-6777(1998)17:5<499::AID-NAU6>3.0.CO;2-8","volume":"17","author":"P Van Kerrebroeck","year":"1998","unstructured":"Van Kerrebroeck P, Amarenco G, Thuroff JW, et al.: Dose-ranging study of tolterodine in patients with detrusor hyperreflexia. Neurourol Urodynam 1998, 17:499\u2013512.","journal-title":"Neurourol Urodynam"},{"key":"25_CR17","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1016\/S0090-4295(98)00629-3","volume":"53","author":"G Larsson","year":"1999","unstructured":"Larsson G, Hallen B, Nilvebrant L: Tolterodine in the treatment of overactive bladder: analysis of the pooled phase II efficacy and safety data. Urology 1999, 53:990\u2013998.","journal-title":"Urology"},{"key":"25_CR18","first-page":"580","volume":"6","author":"P Abrams","year":"2000","unstructured":"Abrams P, Kelleher CJ, Kerr LA, et al.: Overactive bladder significantly affects quality of life. Am J Manag Care 2000, 6:580\u2013590.","journal-title":"Am J Manag Care"},{"key":"25_CR19","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1097\/00003081-200203000-00019","volume":"45","author":"GW Davila","year":"2002","unstructured":"Davila GW, Neimark M: The overactive bladder: prevalence and effects on quality of life. Clin Obstet Gynecol 2002, 45:173\u2013181.","journal-title":"Clin Obstet Gynecol"}],"container-title":["Current Urology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11934-003-0025-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11934-003-0025-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11934-003-0025-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11934-003-0025-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,15]],"date-time":"2022-05-15T12:02:39Z","timestamp":1652616159000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11934-003-0025-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,11]]},"references-count":19,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2003,11]]}},"alternative-id":["25"],"URL":"https:\/\/doi.org\/10.1007\/s11934-003-0025-z","relation":{},"ISSN":["1527-2737","1534-6285"],"issn-type":[{"value":"1527-2737","type":"print"},{"value":"1534-6285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,11]]}}}